Amyloidosis Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Amyloidosis stocks.

Amyloidosis Stocks Recent News

Date Stock Title
Oct 1 ALNY Is Alnylam Pharmaceuticals (ALNY) Stock Outpacing Its Medical Peers This Year?
Oct 1 IONS Ionis gets U.S. FDA fast track designation for its Alexander disease treatment
Oct 1 ALNY Not Holding Alnylam Pharmaceuticals (ALNY) Hurt Fidelity Growth Strategies Fund’s Performance
Oct 1 ABUS Arbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
Oct 1 NTLA Intellia Therapeutics to Present New Clinical Data from the Phase 1 Study of nexiguran ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2024 AHA Scientific Sessions
Oct 1 IONS Zilganersen granted U.S. FDA Fast Track designation for people living with Alexander disease
Oct 1 BBIO 5 FDA decisions to watch in the fourth quarter
Oct 1 SPRC Pharma Company Gets FDA Green Light For Next Phase Trial For Tourette Syndrome
Sep 30 ABOS Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference
Sep 30 BBIO BridgeBio Pharma's Lead Candidate Cuts Mortality, Related Hospitalizations In Patients With Certain Type Of Heart Disease
Sep 30 GMAB Is Genmab A/S (GMAB) One of the Best Revenue Growth Stocks to Buy According to Analysts?
Sep 30 BBIO BridgeBio Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
Sep 29 ALNY Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024
Sep 29 NTLA 2 Innovative Cathie Wood Stocks to Buy If You Can Stomach the Risk
Sep 27 BBIO BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular-related Hospitalization Events
Sep 26 GMAB Grant of Restricted Stock Units and Warrants to Employees in Genmab
Sep 26 ABOS Acumen Pharmaceuticals extends collaboration with Lonza
Sep 26 ABOS Acumen Pharmaceuticals Extends Collaboration with Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer’s Disease
Sep 26 ALNY Alnylam to Webcast TTR Investor Day
Sep 25 NTLA Intellia: Exciting Promise Of First In Vivo Gene Therapy Makes Bull Case
Amyloidosis

Amyloidosis is a disease in which abnormal proteins, known as amyloid fibrils, build up in tissue. There are several types with varying symptoms; signs and symptoms may include diarrhea, weight loss, feeling tired, enlargement of the tongue, bleeding, numbness, feeling faint with standing, swelling of the legs, or enlargement of the spleen.There are about 30 different types of amyloidosis, each due to a specific protein misfolding. Some are genetic while others are acquired. They are grouped into localized forms, and systemic ones. The four most common types of systemic amyloidosis are light chain (AL), inflammation (AA), dialysis-related (Aβ2M), and hereditary and old age (ATTR and familial amyloid polyneuropathy).Diagnosis may be suspected when protein is found in the urine, organ enlargement is present, or problems are found with multiple peripheral nerves and it is unclear why. Diagnosis is confirmed by tissue biopsy. Due to the variable presentation, a diagnosis can often take some time to reach.Treatment is geared towards decreasing the amount of the involved protein. This may sometimes be achieved by determining and treating the underlying cause. AL amyloidosis occurs in about 3–13 per million people per year and AA amyloidosis in about 2 per million people per year. The usual age of onset of these two types is 55 to 60 years old. Without treatment, life expectancy is between six months and four years. In the developed world about 1 per 1,000 people die from amyloidosis. Amyloidosis has been described since at least 1639.

Browse All Tags